Literature DB >> 18768895

Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.

Zuqiang Liu1, Hae S Noh, Janet Chen, Jin H Kim, Louis D Falo, Zhaoyang You.   

Abstract

Administration of anti-CD25 mAb before an aggressive murine breast tumor inoculation provoked effective antitumor immunity. Compared with CD4(+) T cells purified from anti-CD25 mAb-pretreated mice that did not reject tumor, CD4(+) T cells purified from anti-CD25 mAb-pretreated mice that rejected tumor stimulated by dendritic cells (DCs) produced more IFN-gamma and IL-2, and less IL-17 in vitro, and ignited protective antitumor immunity in vivo in an adoptive transfer model. Tumor Ag-loaded DCs activated naive CD8(+) T cells in the presence of these CD4(+) T cells in vitro. Tumor Ag and adoptively transferred CD4(+) T cells were both required for inducing a long-term tumor-specific IFN-gamma-producing cellular response and potent protective antitumor activity. Although adoptively transferred CD4(+) T cells ignited effective tumor-specific antitumor immunity in wild-type mice, they failed to do so in endogenous NK cell-depleted, Gr-1(+) cell-depleted, CD40(-/-), CD11c(+) DC-depleted, B cell(-/-), CD8(+) T cell-depleted, or IFN-gamma(-/-) mice. Collectively, the data suggest that adoptively transferred CD4(+) T cells orchestrate both endogenous innate and adaptive immunity to generate effective tumor-specific long-term protective antitumor immunity. The data also demonstrate the pivotal role of endogenous DCs in the tumor-specific protection ignited by adoptively transferred CD4(+) T cells. Thus, these findings highlight the importance of adoptively transferred CD4(+) T cells, as well as host immune components, in generating effective tumor-specific long-term antitumor activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768895      PMCID: PMC2596715          DOI: 10.4049/jimmunol.181.6.4363

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

Authors:  Noelia Casares; Laura Arribillaga; Pablo Sarobe; Javier Dotor; Ascensión Lopez-Diaz de Cerio; Ignacio Melero; Jesús Prieto; Francisco Borrás-Cuesta; Juan J Lasarte
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

Review 2.  Helping the CD8(+) T-cell response.

Authors:  Michael J Bevan
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

3.  Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.

Authors:  Leo Luznik; Jill E Slansky; Sanju Jalla; Ivan Borrello; Hyam I Levitsky; Drew M Pardoll; Ephraim J Fuchs
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

4.  Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells.

Authors:  Kenji Chamoto; Takemasa Tsuji; Hiromi Funamoto; Akemi Kosaka; Junko Matsuzaki; Takeshi Sato; Hiroyuki Abe; Keishi Fujio; Kazuhiko Yamamoto; Toshio Kitamura; Tsuguhide Takeshima; Yuji Togashi; Takashi Nishimura
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

5.  CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.

Authors:  Réjean Lapointe; Angélique Bellemare-Pelletier; Franck Housseau; Jacques Thibodeau; Patrick Hwu
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

6.  Modulation of tryptophan catabolism by regulatory T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Kwang Woo Hwang; Ciriana Orabona; Carmine Vacca; Roberta Bianchi; Maria Laura Belladonna; Maria Cristina Fioretti; Maria-Luisa Alegre; Paolo Puccetti
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

Review 7.  Vaccines for tumour prevention.

Authors:  Pier-Luigi Lollini; Federica Cavallo; Patrizia Nanni; Guido Forni
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

8.  Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens.

Authors:  Denise Golgher; Emma Jones; Fiona Powrie; Tim Elliott; Awen Gallimore
Journal:  Eur J Immunol       Date:  2002-11       Impact factor: 5.532

9.  Essential roles of tumor-derived helper T cell epitopes for an effective peptide-based tumor vaccine.

Authors:  Lijie Wang; Yoshihiro Miyahara; Takuma Kato; Linan Wang; Takumi Aota; Kagemasa Kuribayashi; Hiroshi Shiku
Journal:  Cancer Immun       Date:  2003-11-21

10.  Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma.

Authors:  Beth A Pulaski; Mark J Smyth; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  16 in total

Review 1.  Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis.

Authors:  Zheng-Xu Wang; Jun-Xia Cao; Zhi-Ping Liu; Yu-Xin Cui; Chun-Yun Li; Duo Li; Xiao-Yan Zhang; Jin-Long Liu; Jun-Li Li
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

2.  Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity.

Authors:  Zuqiang Liu; Louis D Falo; Zhaoyang You
Journal:  J Immunol       Date:  2011-06-03       Impact factor: 5.422

3.  In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.

Authors:  Qiao Li; Seagal Teitz-Tennenbaum; Elizabeth J Donald; Mu Li; Alfred E Chang
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

4.  Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.

Authors:  Mark J Dobrzanski; Kathleen A Rewers-Felkins; Khaliquzzaman A Samad; Imelda S Quinlin; Catherine A Phillips; William Robinson; David J Dobrzanski; Stephen E Wright
Journal:  Cancer Immunol Immunother       Date:  2011-11-15       Impact factor: 6.968

5.  Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression.

Authors:  Qiao Li; Xiangming Lao; Qin Pan; Ning Ning; Ji Yet; Yingxin Xu; Shengping Li; Alfred E Chang
Journal:  Clin Cancer Res       Date:  2011-06-20       Impact factor: 12.531

6.  Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity.

Authors:  Zuqiang Liu; Xingxing Hao; Yi Zhang; Jiying Zhang; Cara D Carey; Louis D Falo; Walter J Storkus; Zhaoyang You
Journal:  Oncoimmunology       Date:  2017-04-24       Impact factor: 8.110

7.  piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.

Authors:  Pallavi V Raja Manuri; Matthew H Wilson; Sourindra N Maiti; Tiejuan Mi; Harjeet Singh; Simon Olivares; Margaret J Dawson; Helen Huls; Dean A Lee; Pulivarthi H Rao; Joseph M Kaminski; Yozo Nakazawa; Stephen Gottschalk; Partow Kebriaei; Elizabeth J Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 8.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

9.  Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation.

Authors:  Zuqiang Liu; Shenghe Tian; Louis D Falo; Shimon Sakaguchi; Zhaoyang You
Journal:  Mol Ther       Date:  2009-05-05       Impact factor: 11.454

10.  Tumor regulatory T cells potently abrogate antitumor immunity.

Authors:  Zuqiang Liu; Jin H Kim; Louis D Falo; Zhaoyang You
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.